search
Back to results

Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects

Primary Purpose

Joint Pain

Status
Recruiting
Phase
Not Applicable
Locations
India
Study Type
Interventional
Intervention
Collagen type II (40 mg/day)
Collagen type II (80mg/day)
Collagen type II (120 mg/day)
Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Placebo
Sponsored by
Vedic Lifesciences Pvt. Ltd.
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional other trial for Joint Pain

Eligibility Criteria

20 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Physically active male and female both, aged ≥ 20 to ≤ 65 years with the daily routine of physical exercise (exercise such as walking, jogging, running, cycling, climbing stairs, squatting or any other exercise on investigator's discretion that involves knee joint movement) for at least 3 days a week.
  2. Subject with a history of 4-9 months related to knee joint pain aggravation on physical stress.
  3. Body mass index (BMI) ≥ 20 and ≤ 29.9 kg/m2.
  4. Fasting blood glucose (FBG) ≤ 125 mg/ dl.
  5. Subject with self-reported joint pain of ≥ 70 mm on a 100-point VAS scale after 10±2 minutes of walking on a treadmill using modified Naughton protocol.
  6. Subject with pain ≤30 mm at rest on Pain VAS
  7. Subject not diagnosed as a case of OA / RA confirmed by the American college of rheumatology (ACR) criteria.
  8. The subject is willing to complete all the study procedures including study-related questionnaires and tasks, and comply with the study requirements.
  9. The subject is willing to abstain from the restricted supplements and medications prior to inclusion and throughout the study period.
  10. Subject with the ability to read and provide written, personally signed, and dated informed consent to participate in the study.

Exclusion Criteria:

  1. Obese Subject with BMI > 29.9 kg/m2.
  2. Subject's inability to complete the exercise protocol of 10±2 minutes at screening.
  3. Subject with the clinical diagnosis of any form of joint disease such as Osteoarthritis (OA).
  4. Subject with the clinical diagnosis of any form of autoimmune disorder related to the joint such as Rheumatoid arthritis (RA).
  5. A subject suffering from Insomnia and restless leg syndrome.
  6. Uncontrolled hypertensive defined as subject currently on an anti-hypertensive drug with systolic Blood Pressure ≥ 140 mm Hg and/ or & diastolic blood pressure ≥ 90 mm Hg
  7. Uncontrolled diabetics currently on anti-diabetic medication with Fasting blood glucose (FBG) ≥ 126 mg/ dl.
  8. Systolic Blood Pressure ≥ 140 mm Hg and/ or & diastolic blood pressure ≥ 90 mm Hg
  9. The subject who have been injured near the knee joint region in the past six months.
  10. Subject with a history of knee surgery, replacement, or any non-knee surgical procedures that may impact the study outcomes.
  11. The subject who have used Intra-articular injections and or steroids for joint health issues in the last six months. The subjects who have undergone a significant cardiovascular event in the past six months.
  12. The subject who has undergone a significant cardiovascular event in the past six months.
  13. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurological disorders, that in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk.
  14. The subject who have any other chronic disease or condition or inflammatory disease conditions and/ or are using any medication or dietary supplements or ayurvedic medications or topical ointment/oil/gel for joint health that in the judgment of the Investigator would put the subject at unacceptable risk the for the subject in the study or may interfere with evaluations in the study or noncompliance with treatment or visits.
  15. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives.
  16. The subject who have participated in a study of an investigational product 90 days prior to the screening.
  17. Subject with a history of heavy alcohol consumption.
  18. Smokers
  19. Subject currently on joint health supplements for pain or inflammation.

Sites / Locations

  • HOS Hospital
  • Shalby hospitalRecruiting
  • Aman Hospital and Research CentreRecruiting
  • BLDEU Hospital and research center
  • Shree Ashirwad HospitalRecruiting
  • Surya HospitalRecruiting
  • Ranka HospitalRecruiting
  • Jivanrekha HospitalRecruiting
  • BAJ RR HospitalRecruiting
  • Jaipur National University Institute of Medical Sciences and Research CenterRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm 5

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Placebo Comparator

Arm Label

Collagen type II (40 mg/day)

Collagen type II (80 mg/day)

Collagen type II (120 mg/day)

Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)

Placebo

Arm Description

4 capsules per day for 180 days

4 capsules per day for 180 days

4 capsules per day for 180 days

4 capsules per day for 180 days

4 capsules per day for 180 days

Outcomes

Primary Outcome Measures

range of motion (active flexion and extension)
To evaluate the efficacy of collagen on knee joint flexibility as assessed by the change in the range of motion (active flexion and extension) using goniometry as compared to placebo.

Secondary Outcome Measures

range of motion knee joint flexibility
Change in the knee joint flexibility (Knee ROM Extension) as assessed by a range of motion (using goniometry) in the Collagen groups versus the other groups
Pain visual analog scale
Knee joint pain as assessed by Pain visual analog scale at the end of the stress exercise in Collagen groups versus the placebo and the Glucosamine & Chondroitin group. 0 - No pain at all 100 - worst possible pain
Knee injury and Osteoarthritis Outcome Score
Retrospective Joint Discomfort as assessed by the change in the Knee injury and Osteoarthritis Outcome Score as compared in the Collagen groups compared to placebo and Glucosamine & Chondroitin. A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0- 100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopedic scales and generic measures. Scores between 0 and 100 represent the percentage of the total possible score achieved
European Quality of Life Five Dimension five-level
Quality of life (QoL) as assessed by change in European Quality of Life Five Dimension five-level score as compared to the change into placebo and Glucosamine & Chondroitin groups Lower level is denoted as 1 and the highest level is denoted as 5

Full Information

First Posted
January 14, 2022
Last Updated
November 29, 2022
Sponsor
Vedic Lifesciences Pvt. Ltd.
search

1. Study Identification

Unique Protocol Identification Number
NCT05212259
Brief Title
Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects
Official Title
A Randomized, Double-Blind, Placebo-controlled, Parallel Design Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects
Study Type
Interventional

2. Study Status

Record Verification Date
November 2022
Overall Recruitment Status
Recruiting
Study Start Date
October 10, 2022 (Actual)
Primary Completion Date
September 15, 2023 (Anticipated)
Study Completion Date
September 15, 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Vedic Lifesciences Pvt. Ltd.

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
A Randomized, Double-Blind, Placebo-controlled, Parallel Design Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Joint Pain

7. Study Design

Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized, Double-Blind, Placebo-controlled, Parallel Design
Masking
ParticipantCare ProviderInvestigator
Masking Description
Envelope blinding chits
Allocation
Randomized
Enrollment
375 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Collagen type II (40 mg/day)
Arm Type
Experimental
Arm Description
4 capsules per day for 180 days
Arm Title
Collagen type II (80 mg/day)
Arm Type
Experimental
Arm Description
4 capsules per day for 180 days
Arm Title
Collagen type II (120 mg/day)
Arm Type
Experimental
Arm Description
4 capsules per day for 180 days
Arm Title
Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Arm Type
Active Comparator
Arm Description
4 capsules per day for 180 days
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
4 capsules per day for 180 days
Intervention Type
Drug
Intervention Name(s)
Collagen type II (40 mg/day)
Intervention Description
4 capsules per day
Intervention Type
Drug
Intervention Name(s)
Collagen type II (80mg/day)
Intervention Description
4 capsules per day
Intervention Type
Drug
Intervention Name(s)
Collagen type II (120 mg/day)
Intervention Description
4 capsules per day
Intervention Type
Drug
Intervention Name(s)
Glucosamine Hydrochloride with Chondroitin Sulphate (2700 mg)
Intervention Description
4 capsules per day
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
4 capsules per day
Primary Outcome Measure Information:
Title
range of motion (active flexion and extension)
Description
To evaluate the efficacy of collagen on knee joint flexibility as assessed by the change in the range of motion (active flexion and extension) using goniometry as compared to placebo.
Time Frame
from baseline Day 0 to end of study visit day 180
Secondary Outcome Measure Information:
Title
range of motion knee joint flexibility
Description
Change in the knee joint flexibility (Knee ROM Extension) as assessed by a range of motion (using goniometry) in the Collagen groups versus the other groups
Time Frame
from baseline (day 0) to end of study visit (day 180)
Title
Pain visual analog scale
Description
Knee joint pain as assessed by Pain visual analog scale at the end of the stress exercise in Collagen groups versus the placebo and the Glucosamine & Chondroitin group. 0 - No pain at all 100 - worst possible pain
Time Frame
from baseline (Day 0) to Day 5, 30, 60, 90, 120, 150 and 180
Title
Knee injury and Osteoarthritis Outcome Score
Description
Retrospective Joint Discomfort as assessed by the change in the Knee injury and Osteoarthritis Outcome Score as compared in the Collagen groups compared to placebo and Glucosamine & Chondroitin. A Likert scale is used and all items have five possible answer options scored from 0 (No problems) to 4 (Extreme problems) and each of the five scores is calculated as the sum of the items included. Scores are transformed to a 0- 100 scale, with zero representing extreme knee problems and 100 representing no knee problems as common in orthopedic scales and generic measures. Scores between 0 and 100 represent the percentage of the total possible score achieved
Time Frame
from baseline (Day 0) (post-exercise) to follow up visit Day 5, 30, 60, 90, 120, 150 and day 180 (post-exercise)
Title
European Quality of Life Five Dimension five-level
Description
Quality of life (QoL) as assessed by change in European Quality of Life Five Dimension five-level score as compared to the change into placebo and Glucosamine & Chondroitin groups Lower level is denoted as 1 and the highest level is denoted as 5
Time Frame
from baseline (Day 0) to the end of the study (day 180)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Physically active male and female both, aged ≥ 20 to ≤ 65 years with the daily routine of physical exercise (exercise such as walking, jogging, running, cycling, climbing stairs, squatting or any other exercise on investigator's discretion that involves knee joint movement) for at least 3 days a week. Subject with a history of 4-9 months related to knee joint pain aggravation on physical stress. Body mass index (BMI) ≥ 20 and ≤ 29.9 kg/m2. Fasting blood glucose (FBG) ≤ 125 mg/ dl. Subject with self-reported joint pain of ≥ 70 mm on a 100-point VAS scale after 10±2 minutes of walking on a treadmill using modified Naughton protocol. Subject with pain ≤30 mm at rest on Pain VAS Subject not diagnosed as a case of OA / RA confirmed by the American college of rheumatology (ACR) criteria. The subject is willing to complete all the study procedures including study-related questionnaires and tasks, and comply with the study requirements. The subject is willing to abstain from the restricted supplements and medications prior to inclusion and throughout the study period. Subject with the ability to read and provide written, personally signed, and dated informed consent to participate in the study. Exclusion Criteria: Obese Subject with BMI > 29.9 kg/m2. Subject's inability to complete the exercise protocol of 10±2 minutes at screening. Subject with the clinical diagnosis of any form of joint disease such as Osteoarthritis (OA). Subject with the clinical diagnosis of any form of autoimmune disorder related to the joint such as Rheumatoid arthritis (RA). A subject suffering from Insomnia and restless leg syndrome. Uncontrolled hypertensive defined as subject currently on an anti-hypertensive drug with systolic Blood Pressure ≥ 140 mm Hg and/ or & diastolic blood pressure ≥ 90 mm Hg Uncontrolled diabetics currently on anti-diabetic medication with Fasting blood glucose (FBG) ≥ 126 mg/ dl. Systolic Blood Pressure ≥ 140 mm Hg and/ or & diastolic blood pressure ≥ 90 mm Hg The subject who have been injured near the knee joint region in the past six months. Subject with a history of knee surgery, replacement, or any non-knee surgical procedures that may impact the study outcomes. The subject who have used Intra-articular injections and or steroids for joint health issues in the last six months. The subjects who have undergone a significant cardiovascular event in the past six months. The subject who has undergone a significant cardiovascular event in the past six months. History or presence of clinically significant renal, hepatic, endocrine, biliary, gastrointestinal, pancreatic, or neurological disorders, that in the judgment of the Investigator, would interfere with the subject's ability to provide informed consent, comply with the study protocol (which might confound the interpretation of the study results), or put the subject at undue risk. The subject who have any other chronic disease or condition or inflammatory disease conditions and/ or are using any medication or dietary supplements or ayurvedic medications or topical ointment/oil/gel for joint health that in the judgment of the Investigator would put the subject at unacceptable risk the for the subject in the study or may interfere with evaluations in the study or noncompliance with treatment or visits. Females who are pregnant/planning to be pregnant/lactating or taking any oral contraceptives. The subject who have participated in a study of an investigational product 90 days prior to the screening. Subject with a history of heavy alcohol consumption. Smokers Subject currently on joint health supplements for pain or inflammation.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shalini srivastava, MD - Medicine
Phone
02242172300
Email
shalini.s@vediclifesciences.com
First Name & Middle Initial & Last Name or Official Title & Degree
Dr. Sonali Ghosh, BAMS
Phone
02242172300
Email
sonali.g@vediclifesciences.com
Facility Information:
Facility Name
HOS Hospital
City
Ahmedabad
State/Province
Gujarat
ZIP/Postal Code
380006.
Country
India
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Shabbir Sabuwala, MS ortho
Phone
9712940025
Email
drsksabuwala@gmail.com
First Name & Middle Initial & Last Name & Degree
Dr. Shabbir Sabuwala, MS ortho
Facility Name
Shalby hospital
City
Sūrat
State/Province
Gujarat
ZIP/Postal Code
395009.
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Kush Vyas, MBBS D ORTHO
Email
clinicalresearch3.surat@shalby.in
First Name & Middle Initial & Last Name & Degree
Dr. Kush Vyas, MBBS D ORTHO
Facility Name
Aman Hospital and Research Centre
City
Vadodara
State/Province
Gujarat
ZIP/Postal Code
390021
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Aman Khanna, MBBS
Phone
9904402122
Email
amankhanna1974@gmail.com
First Name & Middle Initial & Last Name & Degree
Dr. Aman Khanna, MBBS
Facility Name
BLDEU Hospital and research center
City
Bijapur
State/Province
Karnataka
ZIP/Postal Code
586101
Country
India
Individual Site Status
Not yet recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Shreepad Kulkarni, D ortho
Phone
9964670630
Email
orthoshree@gmail.com
First Name & Middle Initial & Last Name & Degree
Dr Shreepad Kulkarni, D ortho
Facility Name
Shree Ashirwad Hospital
City
Dombivli
State/Province
Maharashtra
ZIP/Postal Code
421201
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Shailesh Talele, MBBS
Phone
9820809180
Email
shaileshtalele@yahoo.co.in
First Name & Middle Initial & Last Name & Degree
Dr Shailesh Talele, MBBS
Facility Name
Surya Hospital
City
Nashik
State/Province
Maharashtra
ZIP/Postal Code
400003.
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Rohit Sonawane, MBBS
Phone
9225109679
Email
srgnosteon@gmail.com
First Name & Middle Initial & Last Name & Degree
Dr Rohit Sonawane, MBBS
Facility Name
Ranka Hospital
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
411037
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Ramesh Ranka, MBBS
Phone
9823049074
Email
ramesh.ranka@yahoo.co.in
First Name & Middle Initial & Last Name & Degree
Dr Ramesh Ranka, MBBS
Facility Name
Jivanrekha Hospital
City
Pune
State/Province
Maharashtra
ZIP/Postal Code
412101
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Ajay Dombale, MBBS
Phone
7741810820
Email
drajay9582@gmail.com
First Name & Middle Initial & Last Name & Degree
Dr Ajay Dombale, MBBS
Facility Name
BAJ RR Hospital
City
Thāne
State/Province
Maharashtra
ZIP/Postal Code
400053
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr Prashant Deshpande, M B B S
Phone
9167432672
Email
drprashantd1981@yahoo.com
First Name & Middle Initial & Last Name & Degree
Dr Prashant Deshpande, M B B S
Facility Name
Jaipur National University Institute of Medical Sciences and Research Center
City
Jaipur
State/Province
Rajasthan
ZIP/Postal Code
302017
Country
India
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Dr. Ankesh Goyal, DNB ortho
Phone
7060924809
Email
clinicalresearch@jnujaipur.ac.in
First Name & Middle Initial & Last Name & Degree
Dr. Ankesh Goyal, DNB ortho

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Clinical Study to Evaluate the Effect of Different Doses of UC-II® Supplementation on the Range of Motion & Joint Discomfort in Healthy Subjects

We'll reach out to this number within 24 hrs